ZA200704391B - Treatment and control of severe infections including cystic fibrosis - Google Patents

Treatment and control of severe infections including cystic fibrosis

Info

Publication number
ZA200704391B
ZA200704391B ZA200704391A ZA200704391A ZA200704391B ZA 200704391 B ZA200704391 B ZA 200704391B ZA 200704391 A ZA200704391 A ZA 200704391A ZA 200704391 A ZA200704391 A ZA 200704391A ZA 200704391 B ZA200704391 B ZA 200704391B
Authority
ZA
South Africa
Prior art keywords
treatment
control
cystic fibrosis
infections including
severe infections
Prior art date
Application number
ZA200704391A
Other languages
English (en)
Inventor
Chaudhary Manu
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of ZA200704391B publication Critical patent/ZA200704391B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200704391A 2005-05-13 2007-05-29 Treatment and control of severe infections including cystic fibrosis ZA200704391B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1241DE2005 2005-05-13

Publications (1)

Publication Number Publication Date
ZA200704391B true ZA200704391B (en) 2008-08-27

Family

ID=37056540

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704391A ZA200704391B (en) 2005-05-13 2007-05-29 Treatment and control of severe infections including cystic fibrosis

Country Status (10)

Country Link
US (1) US20080227732A1 (ko)
EP (1) EP1879589A2 (ko)
JP (1) JP2008540515A (ko)
KR (1) KR20080004589A (ko)
CN (1) CN101080230A (ko)
AU (1) AU2006245302A1 (ko)
BR (1) BRPI0612447A2 (ko)
MX (1) MX2007014191A (ko)
WO (1) WO2006120705A2 (ko)
ZA (1) ZA200704391B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
DK2268142T3 (en) 2007-11-27 2017-05-22 Algipharma As USING ALGINATED OLIGOMERS TO FIGHT BIOFILM
RU2521391C2 (ru) * 2008-09-18 2014-06-27 Ману ЧАУДХАРИ Новые однократные единичные составы карбапенема и аминогликозида
RU2016109404A (ru) 2009-06-03 2018-11-26 АльгиФарма АС Обработка акинетобактерий альгинатными олигомерами и антибиотиками
CN101904822B (zh) * 2009-06-04 2011-11-09 鲁南制药集团股份有限公司 一种法罗培南钠冻干粉针及其制备方法
GB201208080D0 (en) * 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
CN103110641A (zh) * 2013-02-04 2013-05-22 海南中元堂医药科技有限公司 一种注射用头孢地嗪钠和盐酸利多卡因注射液的药物组合物
CN105147599B (zh) * 2015-09-21 2018-07-27 成都天台山制药有限公司 硫酸奈替米星注射液和制法
CN105213301B (zh) * 2015-09-21 2018-07-27 成都天台山制药有限公司 硫酸奈替米星注射液及其质控方法
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
WO2021097077A1 (en) * 2019-11-15 2021-05-20 The Regents Of The University Of California Short conjugated oligoelectrolytes and antibiotics
CN113425678B (zh) * 2021-08-04 2023-02-10 珠海润都制药股份有限公司 一种盐酸去甲乌药碱注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858589B2 (en) * 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US5741782A (en) * 1996-03-29 1998-04-21 Cryolife, Inc. Antibiotic cocktail and method of use
JP2008524204A (ja) * 2004-12-17 2008-07-10 ヴィーナス・レメディーズ・リミテッド 感染の処置に全面的解決を与えるための抗生物質の組合せ
KR20070085674A (ko) * 2005-02-14 2007-08-27 비너스 레머디스 리미티드 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Also Published As

Publication number Publication date
EP1879589A2 (en) 2008-01-23
WO2006120705A3 (en) 2007-03-29
BRPI0612447A2 (pt) 2010-11-23
WO2006120705A2 (en) 2006-11-16
WO2006120705B1 (en) 2007-05-24
KR20080004589A (ko) 2008-01-09
JP2008540515A (ja) 2008-11-20
AU2006245302A1 (en) 2006-11-16
MX2007014191A (es) 2008-02-07
CN101080230A (zh) 2007-11-28
US20080227732A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
ZA200704391B (en) Treatment and control of severe infections including cystic fibrosis
IL257622B (en) Methods and preparations for the treatment of persistent infections
LT1951272T (lt) Lactobacillus panaudojimas virusinių infekcijų gydymui
IL191795A0 (en) The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
IL179873A0 (en) Methods of treatment of endobronchial infections
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
IL186599A0 (en) Methods for treating and preventing fibrosis
EP1986952A4 (en) METHOD FOR THE TREATMENT OF MUCOVISCIDOSIS
ZA200706238B (en) Prevention and treatment of thromboembolic disorders
ZA200802934B (en) Use of lactobacillus for treatment of virus infections
EP1978099A4 (en) ANTIBACTERIAL SUBSTANCE DM0507 AND ITS USE
GB0513096D0 (en) Treatment of microbial infections
GB0619500D0 (en) Treatment of fibrosis
PT2007895E (pt) Construção
IL189171A (en) Use of Fat-Glycosaminoglycan or Fat-Carboxymethyl Cellulose Couplings for the Treatment of Cystic Fibrosis Treatment
ZA200709024B (en) Method of well treatment and construction
IL180459A0 (en) Treatment of bacterial infections
IL196983A0 (en) Treatment and prevention of intestinal fibrosis
GB0720997D0 (en) Methods of altering gene expression and methods of treatment utilizing same
EP1951282A4 (en) TREATMENT OF HYPERSENSITIVITY
GB0504333D0 (en) Treatment of cytokine dysregulation
AU2003291565A8 (en) Polyionenes for treating infections associated with cystic fibrosis
AU2003215146A8 (en) Snares and methods of controlling cytokinesis
AU2004903188A0 (en) Treatment of myocardial fibrosis
GB0517027D0 (en) Provision of medicines and treatment